EGFR and lung carcinoma: In addition, upregulation of the TPX2-S121 and S125 sites likely correlated with the reported role of AURKA kinase and its coactivator TPX2 in response to chronic EGFR inhibition to mitigate drug-induced apoptosis in resistant lung cancer cells39.